Skip to main content

Table 2 Prevalence of different lesions according to the per-protocol analysis

From: Initial results from a multi-center population-based cluster randomized trial of esophageal and gastric cancer screening in China

Pathological diagnosis

Cases N (%)

High-risk areas N (%)

Non-high-risk areas N (%)

P value

All subjects under endoscopy

37,922

26,633

11,289

 

Esophagus

 Esophagitis

4349 (11.5)

4173 (15.7)

176 (1.6)

< 0.001

 Mild/moderate dysplasia, or dysplasia, NOS

1692 (4.5)

1600 (6.0)

92 (0.8)

< 0.001

 Severe dysplasia/EC in situ

195 (0.5)

187 (0.7)

8 (0.1)

< 0.001

 EC

59 (0.2)

52 (0.2)

7 (0.1)

0.003

Positive esophageal lesions

254 (0.7)

239 (0.9)

15 (0.1)

< 0.001

Stomach

 Atrophic gastritis

5522 (14.6)

5132 (19.3)

390 (3.5)

< 0.001

 Intestinal metaplasia/low-grade dysplasia

2977 (7.9)

2257 (8.5)

720 (6.4)

< 0.001

 High-grade dysplasia

117 (0.3)

105 (0.4)

12 (0.1)

< 0.001

 GC

167 (0.4)

143 (0.5)

24 (0.2)

< 0.001

Positive stomach lesions

284 (0.8)

248 (0.9)

36 (0.3)

< 0.001

Positive cases in totala

528 (1.4)

478 (1.8)

50 (0.4)

< 0.001

  1. aTen positive cases had advanced lesions both at esophageal and stomach site